Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.
Trahair TN, Lock RB, Sutton R, Sia KC, Evans K, Richmond J, Law T, Venn NC, Irving JA, Moore S, Nievergall E, Dang P, Heatley SL, White DL, Revesz T. Trahair TN, et al. Among authors: sutton r. Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16. Bone Marrow Transplant. 2016. PMID: 27183096 No abstract available.
Mechanism of relapse in pediatric acute lymphoblastic leukemia.
Henderson MJ, Choi S, Beesley AH, Sutton R, Venn NC, Marshall GM, Kees UR, Haber M, Norris MD. Henderson MJ, et al. Among authors: sutton r. Cell Cycle. 2008 May 15;7(10):1315-20. doi: 10.4161/cc.7.10.5885. Epub 2008 Feb 29. Cell Cycle. 2008. PMID: 18418081
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.
Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, Wilczek V, Budgen B, van Zanten K, Kuss BJ, Venn NC, Norris MD, Crock C, Storey C, Revesz T, Waters K. Morley AA, et al. Among authors: sutton r. J Mol Diagn. 2009 May;11(3):201-10. doi: 10.2353/jmoldx.2009.080048. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324989 Free PMC article.
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA. Brisco MJ, et al. Among authors: sutton r. J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324994 Free PMC article.
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD; Australian and New Zealand Children's Oncology Group. Sutton R, et al. Br J Haematol. 2009 Aug;146(3):292-9. doi: 10.1111/j.1365-2141.2009.07744.x. Epub 2009 Jun 3. Br J Haematol. 2009. PMID: 19500099 Free article. Clinical Trial.
1,940 results